Genetically engineered distal airway stem cell transplantation protects mice from pulmonary infection. Issue 1 (29th November 2019)

• Record Type: Journal Article
• Authors: Zhou, Yue‐qing; Shi, Yun; Yang, Ling; Sun, Yu‐fen; Han, Yu‐fei; Zhao, Zi‐xian; Wang, Yu‐jia; Liu, Ying; Ma, Yu; Zhang, Ting; Ren, Tao; Dale, Tina P; Forsyth, Nicholas R; Jin, Fa‐guang; Qu, Jie‐ming; Zuo, Wei; Xu, Jin‐fu
• Is Part Of: EMBO molecular medicine. Volume 12:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-11-29
• Subjects: antimicrobial peptide -- distal airway stem cells -- pulmonary infection -- transplantation; Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.201810233
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract: Severe pulmonary infection is a major threat to human health accompanied by substantial medical costs, prolonged inpatient requirements, and high mortality rates. New antimicrobial therapeutic strategies are urgently required to address the emergence of antibiotic resistance and persistent bacterial infections. In this study, we show that the constitutive expression of a native antimicrobial peptide LL‐37 in transgenic mice aids in clearing Pseudomonas aeruginosa (PAO1), a major pathogen of clinical pulmonary infection. Orthotopic transplantation of adult mouse distal airway stem cells (DASCs), genetically engineered to express LL‐37, into injured mouse lung foci enabled large‐scale incorporation of cells and long‐term release of the host defense peptide, protecting the mice from bacterial pneumonia and hypoxemia. Further, correlates of DASCs in adult humans were isolated, expanded, and genetically engineered to demonstrate successful construction of an anti‐infective artificial lung. Together, our stem cell‐based gene delivery therapeutic platform proposes a new strategy for addressing recurrent pulmonary infections with future translational opportunities. Synopsis: Using adult distal airway stem cells (DASCs) as a natural vehicle to deliver the antimicrobial peptide LL‐37 into damaged lung, this study reports a technology to restore epithelium barrier and pulmonary innate immunity, which could have applications for the treatment of infectious lung diseases. Bacterial clearance ability was greater in the lungs of LL‐37 transgenic mice compared to those of wild‐type mice. Genetically engineered DASCs expressing LL‐37 peptide displayed normal stem cell properties and enhanced anti‐microbial functions. Orthotopic transplantation of LL‐37‐expressing DASCs was successfully used for lung regeneration and enhanced host defense capability. Bioengineered artificial lungs were protected from bacterial infection by LL‐37‐expressing human DASC engraftment. Abstract : Using adult distal airway stem cells (DASCs) as a natural vehicle to deliver the antimicrobial peptide LL‐37 into damaged lung, this study reports a technology to restore epithelium barrier and pulmonary innate immunity, which could have applications for the treatment of infectious lung diseases.